Showing results 1-10 of 71 for 'cancer-treatment'
Read about Prof. Idit Shachar's search for an improved treatment for chronic lymphocytic leukemia and other blood cancers. She and her team discovered a blocking antibody that showed great promise in killing cancer cells in a clinical trial. Prof. Shachar also addresses the challenges of being a woman (and mom) in science. This is WeizmannViews Issue No. 45.
Looking back at 2016 reveals an exceptional year at the Weizmann Institute, one chock-full of major developments from unprecedented insight into our universe to better understanding of our modern world to truly life-changing – and life-saving – breakthroughs in cancer and medical research. Here are some highlights.
The fine art of mixing drug cocktails - such as for cancer treatment - is incredibly complicated, especially once you get into three or more ingredients. The numbers of possible interactions and side effects are virtually infinite. Now, a new model from the lab of Prof. Uri Alon lets scientists compare combinations of drugs to determine which work well together, and with the fewest side effects. This is a major step forward in personalized medicine.
Triple-negative breast cancer is particularly hard to treat because, as its name suggests, it lacks three receptors that usually serve as targets for anti-cancer drugs. Now, Prof. Sima Lev has identified a promising new combination therapy that not only inhibits tumor growth and survival, but gets around the problem of drug-induced resistance.
October is National Breast Cancer Awareness Month, and people everywhere are running, walking, and even shopping in support – and, at the Weizmann Institute of Science, investigating, researching, and pursuing creative new ways to attack this still-insidious, too-common disease.
Our devoted scientists are developing ways to detect breast cancer early, designing more effective treatments, and better preventing it in the first place. Learn what Weizmann is doing about breast cancer – and how you can help.
As Britain’s Royal Pharmaceutical Society reports in its Pharmaceutical Journal, researchers working on T-cell therapies for cancer – such as Weizmann’s Prof. Zelig Eshhar – were snubbed for years… until now. This thorough overview of the field’s beginning – including in Prof. Eshhar’s lab – and its future makes clear the importance of T cells.
Prof. Zelig Eshhar, whose basic research led to the creation of cancer-killing T-cells, is one of six scientists to receive a 2016 Novartis Prize for Immunology. Announced and granted by the healthcare and pharma company, the prestigious prizes are “awarded every three years for breakthrough contributions to the fields of basic and clinical immunology.”
Two Weizmann PhDs are behind Nucleix, an Israeli company that has designed a simple test for monitoring bladder cancer – the most expensive cancer to treat over a patient’s lifetime. Called “Bladder EpiCheck,” the method is in advanced clinical trials in The Netherlands, Germany, Spain, and Israel, reports Israel21c – and is heading for the U.S.